Your browser does not support iframes.
A new study made possible through Teva’s partnership with Mount Sinai’s Arnhold Institute for Global Health offers a novel method for identifying patterns in the frequency and cost of multiple chronic conditions (MCC), the presence of two or more chronic conditions in one individual.
Republished with permission from Medicines for Europe - 25 September, 2019
Immediately calls on new President of EU Commission to prioritise Healthcare
First action to call on newly appointed President Elect of European Commission Ursula von der Leyen to establish a new pharmaceutical forum focused on sustainable access to medicines for all EU citizens
Migraine is a complex and debilitating neurological disease that affects an estimated one billion people worldwide.
Find out more about the condition here, including information on the symptoms, treatment options, impact of migraine on patients and Teva’s expertise in this area.
Meet Kris Van Deuren. As part of the Global Corporate Security team, Kris leads Teva’s worldwide efforts to protect patients from potentially toxic fake drugs. He collaborates with international agencies to hunt down and dismantle billion dollar counterfeit drug operations.
Meet Ann Lee-Jeffs, Teva’s Senior Director for Environment and Product Stewardship. Ann’s mission is a challenging one – to ensure that the process of filling the one of the world’s largest medicine cabinets has a positive impact on both people and the planet.
Meet Ed Kinkler. As Senior Manager for Logistics Chain and Product Security in the Americas, Ed’s role is to ensure that Teva’s medicines are stored and transported to their destinations safely. He is fighting a constant battle with criminals who want to get their hands on these highly valuable products.
At Teva, we strive to improve the lives of our patients and go beyond our medicines to create a healthier world. Our recently released 2018 Social Impact Report details our efforts and progress to make a positive impact. We sat down with Amalia Adler-Waxman, Vice President, Social Impact & Responsibility to learn more about the report and how Teva is making a difference.
Multiple sclerosis is a chronic, unpredictable and progressive disease of the Central Nervous System, which is made up of the brain and spinal cord.Find out more about the disease here, including the different types of MS, what the symptoms are, who is affected, how they cope and Teva’s expertise in this area.
It can take up to 15 years to develop a new medicine, with rigorous investigations carried out along the way to monitor and improve its effectiveness and safety. But we don’t stop there – we keep monitoring medicines after they become available to patients to check there aren’t any unexpected side effects.
As Teva’s Senior Pharmacovigilance Professional, it’s Vanesa Ivetic Tkalcevic’s job to investigate cases where the unexpected does occur, find out what happened and make recommendations to help keep patients safe in the future.
Discussion highlights multiple chronic conditions as central to Universal Health Coverage
In February 2019, Peru was again hit by severe flooding, but Teva’s local distribution team was ready, thanks to some hard lessons learned during the previous storms, just two years before.
Jack de Graaf heads up Teva’s Environment, Health and Safety (EHS) function in Europe. It’s his job to make sure the firm’s many European factories, R&D sites, and offices are safe to work in. Here he talks about keeping 14,000 people safe, the potential for disaster if things go wrong… and why he feels a bit like Teva’s mother.